Yagnesh Patel
About Yagnesh Patel
Yagnesh Patel is the Director of Biologics CMC at Bristol Myers Squibb, with over 25 years of experience in the pharmaceutical and biotechnology industry. He specializes in the development and manufacturing of biologics and has a strong background in analytical chemistry and method development.
Current Role at Bristol Myers Squibb
Yagnesh Patel serves as the Director of Biologics CMC at Bristol Myers Squibb. Since joining the company in 2014, he has been leading the Biologics CMC team, contributing to the development of several key biologics products. His role involves overseeing the Chemistry, Manufacturing, and Controls (CMC) requirements crucial for biologics development.
Previous Experience at Merck
Yagnesh Patel worked at Merck from 2007 to 2014 as an Associate Director of Biologics CMC. During his seven-year tenure, he gained substantial experience in biologics development and manufacturing, focusing on regulatory submissions and compliance. His time at Merck bolstered his expertise in managing complex biologics projects.
Early Career in the Pharmaceutical Industry
Yagnesh Patel embarked on his career in the pharmaceutical industry at Shire Pharmaceuticals, where he worked as an Analytical Supervisor from 1999 to 2003. He subsequently joined Clay Park Labs as an ARD Supervisor, and later, as a Senior Scientist at Perrigo following the acquisition of Clay Park Labs. His roles spanned analytical method development and compliance, building a solid foundation in pharmaceutical sciences.
Educational Background
Yagnesh Patel holds a Ph.D. in Analytical Chemistry from the University of Mumbai, which he completed between 1995 and 1998. He also obtained a BSc and MSc in Chemistry from I. Y. College and studied at Xaviers. His educational background laid the groundwork for his extensive career in analytical chemistry and biologics.
Specialization in Biologics Development
With over 25 years of experience in the pharmaceutical and biotechnology industries, Yagnesh Patel specializes in the development and manufacturing of biologics. He has extensive experience in regulatory submissions and compliance, a strong background in analytical chemistry, and has contributed to multiple successful product launches. His deep understanding of CMC requirements has been instrumental in implementing innovative technologies in biologics manufacturing.